ArticleBMC musculoskeletal disorders2023
Association of apolipoprotein A1 with osteoporosis: a cross-sectional study.
Article in BMC musculoskeletal disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- ApoA1 and ApoB Are Associated with Fracture Risk in Patients with Type 1 Diabetes.Journal of clinical medicine · 2026Article
- SHBG and APOA1 as serum biomarkers for low bone mineral density in Mexican postmenopausal women: a random forest-based analysis.Frontiers in endocrinology · 2026Article
- A threshold effect of Apolipoprotein A1 levels on systemic inflammatory response index in individuals with osteoporotic fractures: a cross-sectional study.BMC musculoskeletal disorders · 2025Article
- Association Between Serum Apolipoprotein B and Bone Mineral Density and the Effects of Cardiovascular Disease Mediation: Results From the NHANES 2011-2016 and a Mendelian Randomization Study.Reviews in cardiovascular medicine · 2025Article
- Causal Relationship Between Blood Metabolites and Osteoporosis: A Two-Sample Mendelian Randomization and Genetic Correlation Analysis.Bioengineering (Basel, Switzerland) · 2025Article
- The diagnostic value of the combined application of blood lipid metabolism markers and interleukin-6 in osteoporosis and osteopenia.Lipids in health and disease · 2025Article
- U-Shaped association between apolipoprotein A1 and serum uric acid levels in patients with osteoporotic fractures: a cross-sectional study.Frontiers in endocrinology · 2025Article
- Associations of Serum Lipid Traits With Fracture and Osteoporosis: A Prospective Cohort Study From the UK Biobank.Journal of cachexia, sarcopenia and muscle · 2024Article
- Nonlinear relationship between cardiometabolic index and bone mineral density in U.S. adults: the mediating role of percent body fat.Scientific reports · 2024Article
- Association between hypertension and osteoporosis: a population-based cross-sectional study.BMC musculoskeletal disorders · 2024Article
- Label-free quantitative proteomics in serum reveals candidate biomarkers associated with low bone mineral density in Mexican postmenopausal women.GeroScience · 2024Article
- Association of apolipoprotein A1 levels with lumbar bone mineral density and β-CTX in osteoporotic fracture individuals: a cross-sectional investigation.Frontiers in medicine · 2024Article
- Associations between apolipoprotein B and bone mineral density: a population-based study.BMC musculoskeletal disorders · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Higher levels of apolipoprotein A1 (ApoA1) were associated with higher risk of osteoporosis, which supports the argument that lipid metabolism is involved in bone metabolism.
backgroundAlthough the current evidence shows that lipid metabolism and osteoporosis are closely related to cardiovascular disease, the association between ApoA1 and osteoporosis is still unknown. Therefore, the purpose of this study was to explore the relationship between ApoA1 and osteoporosis.
methodsIn this cross-sectional study, we included 7743 participants in the Third National Health and Nutrition Examination Survey. ApoA1 was regarded as an exposure variable and osteoporosis was considered as an outcome variable. Multivariate logistic regression analysis, sensitivity analysis, and receiver operator characteristic (ROC) were used to assess the association of ApoA1 with osteoporosis.
resultsParticipants with higher ApoA1 had higher rates of osteoporosis compared to participants with lower ApoA1 (P < 0.05). Individuals with osteoporosis had higher levels of ApoA1 than individuals without osteoporosis (P < 0.05). In multivariate logistic regression analysis adjusted for age, sex, race, hypertension, diabetes, gout, hypotensive drugs, hypoglycemic drugs, systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, apolipoprotein B, blood urea nitrogen, albumin, uric acid, hemoglobin A1c, alkaline phosphatase and total calcium, higher ApoA1 was strongly associated with higher risk of osteoporosis, whether as a continuous variable or a categorical variable [Model 3, OR (95% CI), P value: 2.289 (1.350, 3.881), 0.002 and 1.712 (1.183, 2.478), 0.004]. And after excluding individuals with gout, the correlation between them remained and was significant (P < 0.01). And ROC analysis also showed that ApoA1 could predict the development of osteoporosis (AUC = 0.650, P < 0.001).
conclusionApoA1 was closely associated with osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.